Working… Menu

Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02728440
Recruitment Status : Completed
First Posted : April 5, 2016
Last Update Posted : April 13, 2016
Information provided by (Responsible Party):
Aydogan Aydogdu, Gulhane School of Medicine

Brief Summary:
Effects of gonadotrophin replacement therapy Lipid Profile and Oxidative Stress Parameters of Patients with Idiopathic Hypogonadotropic Hypogonadism

Condition or disease Intervention/treatment
Idiopathic Hypogonadotropic Hypogonadism Drug: human chorionic gonadotropin, human menopausal gonadotropin

Detailed Description:
30 male patients diagnosed with IHH and a control group of 20 healthy cases with similar age and BMI were included in the study. The levels of advanced oxidation protein products (AOPP), thiol, malondialdehyde (MDA), nitric oxide (NO) and 8-hydroxydeoxyguanosine (8-OHdG) and the levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-K), low density lipoprotein (LDL-K), Apolipoprotein A1 (ApoA1) and Apolipoprotein B100 (ApoB100) were measured before and after gonadotrophin therapy.

Layout table for study information
Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Lipid Profile and Oxidative Stress Parameters of Patients With Idiopathic Hypogonadotropic Hypogonadism and the Change of These Parameters With Gonadotropin Replacement Therapy
Study Start Date : May 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Hypogonadotropic hypogonadism patients
30 patients with idiopathic hypogonadotrophic hypogonadism
Drug: human chorionic gonadotropin, human menopausal gonadotropin
drug for the treatment of male hypogonadism
Other Names:
  • Pregnyl ® Organon hCG 1500 IU
  • Merional ® ARIS 75 IU

Primary Outcome Measures :
  1. oxidative stress after hCG and HMG treatment [ Time Frame: 2010-2012 ]
  2. HDL levels after hCG treatment [ Time Frame: 2010-2012 ]
  3. total cholesterole levels after hCG treatment [ Time Frame: 2010-2012 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with Idiopathic Hypogonadotropic Hypogonadism and healthy control group

Inclusion Criteria:

Serum testosterone concentration < 300ng/dL Absence of a pituitary or hypothalamic mass lesions, Presence of gonadotropin response to GnRH, -

Exclusion Criteria:

diabetes mellitus, arterial hypertension other hormone deficiencies


Layout table for additonal information
Responsible Party: Aydogan Aydogdu, MD, Gulhane School of Medicine Identifier: NCT02728440    
Other Study ID Numbers: FB03232016
First Posted: April 5, 2016    Key Record Dates
Last Update Posted: April 13, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Chorionic Gonadotropin
Reproductive Control Agents
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents